Pärsson H, Holmberg A, Siegbahn A, Bergqvist D
Institution for Surgical Science, Uppsala, Sweden.
Eur J Vasc Endovasc Surg. 2004 Feb;27(2):186-92. doi: 10.1016/j.ejvs.2003.10.015.
To study the activation of coagulation and fibrinolysis before, during and after surgical revascularisation in patients with critical limb ischemia (CLI).
Prospective clinical study.
Forty patients with CLI underwent femoro-popliteal or femoro-distal reconstruction and were compared to a control-group. Measurements of prothrombin-fragment 1+2 (F1+2) and thrombin-antithrombin complex (TAT) assessed activation of coagulation. Fibrinolysis was determined by tissue plasminogen activator (tPA), plasminogen activator inhibitor (PAI-1) and fibrin degradation product (D-dimer). The inflammatory mediators: Interleukin 2 receptor (IL-2-rec), Interleukin 6 (IL-6), Interleukin 10 (IL-10) and Monocyte chemoattractant protein 1 (MCP-1) was also analysed.
Patients (in 35 of the 40 reconstruction was possible) were operated upon using either vein (n=23) or ePTFE (n=12) grafts. Patients with CLI had a preoperative prothrombotic state as indicated by high TAT-levels and also ongoing fibrinolysis with high levels of t-PA and D-dimer. After reperfusion an ongoing prothrombotic state for the first week was demonstrated. A significant as well as defective fibrinolysis was also seen with increased levels of tPA and D-dimer unopposed by PAI-1 after one week and also after 30 days. Increased levels of inflammatory mediators IL-6, IL-10 and MCP-1 was observed after reperfusion and normalised after 30 days.
This study demonstrates significant disturbances of both the coagulation and fibrinolytic systems before, during and after revascularisation for CLI. This was accompanied by release of inflammatory mediators. A prothrombotic state and increased fibrinolysis were evident also 30 days after successful revascularisation.
研究严重肢体缺血(CLI)患者手术血运重建术前、术中和术后凝血及纤溶的激活情况。
前瞻性临床研究。
40例CLI患者接受股腘或股远端重建手术,并与对照组进行比较。通过凝血酶原片段1+2(F1+2)和凝血酶 - 抗凝血酶复合物(TAT)的测量评估凝血激活情况。通过组织纤溶酶原激活物(tPA)、纤溶酶原激活物抑制剂(PAI - 1)和纤维蛋白降解产物(D - 二聚体)测定纤溶情况。还分析了炎症介质:白细胞介素2受体(IL - 2 - rec)、白细胞介素6(IL - 6)、白细胞介素10(IL - 10)和单核细胞趋化蛋白1(MCP - 1)。
患者(40例中有35例可行重建手术)使用静脉移植物(n = 23)或ePTFE移植物(n = 12)进行手术。CLI患者术前呈现血栓前状态,表现为TAT水平升高,同时存在高水平t - PA和D - 二聚体的持续纤溶。再灌注后,第一周呈现持续的血栓前状态。一周后以及30天后,还观察到显著且有缺陷的纤溶,tPA和D - 二聚体水平升高,而PAI - 1未起到相应抑制作用。再灌注后炎症介质IL - 6、IL - 10和MCP - 1水平升高,并在30天后恢复正常。
本研究表明,CLI血运重建术前、术中和术后凝血和纤溶系统均存在显著紊乱。同时伴有炎症介质的释放。成功血运重建30天后,血栓前状态和纤溶增加仍很明显。